Humacyte, Inc.
NASDAQ: HUMA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laura E. Niklason
- Employees
- 218
- Headquarters
- Durham, United States
- IPO year
- 2020
- Market cap
- $117.2M
- Website
- https://www.humacyte.com
Loading HUMA…
Loading profile data…Frequently asked questions about HUMA
What does Humacyte, Inc. (HUMA) do?
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary t...
Where does HUMA trade?
Humacyte, Inc. (HUMA) trades on the NASDAQ Global Select.
What sector is HUMA in?
Humacyte, Inc. (HUMA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Humacyte, Inc.?
Laura E. Niklason is the chief executive officer of Humacyte, Inc. (HUMA).
Where is Humacyte, Inc. headquartered?
Humacyte, Inc. is headquartered in United States.
Does HUMA pay a dividend?
Humacyte, Inc. (HUMA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HUMA go public?
Humacyte, Inc. (HUMA) completed its initial public offering in 2020.